Psychedelics

Magic Mushrooms in laboratory. Psilocybin science and research.
#Depression #Plant-based #Psilocybin #Psychedelics #Treatment-resistant depression

Where is the promise for plant-based medicines? Part 2: Psilocybin 

In the second part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of psilocybin in drug discovery. The first part explored medical cannabis.  What is the regulatory landscape of psilocybin?  Psilocybin is a naturally occurring psychedelic compound that is produced by more than… Read More

#Business & Investment #Exclusive Content #Regulatory

#Clinical trial #Cybin #Major depressive disorder #Psychedelics

Another milestone achieved in major depressive disorder trial 

Cybin, a clinical-stage biopharmaceutical company developing psychedelic-based treatment options for mental health, has completed dosing in Cohort 5 of a Phase II trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (MDD).   The dosing was completed with no… Read More

#News

Magic mushrooms
#Clinical trial design #Clinical trials #FDA #Psychedelics

FDA recommendations to inform psychedelic drug development

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. This is the first FDA draft guidance that presents considerations to industry for… Read More

#News #Regulatory

Woman with alcohol use disorder
#Beckley Psytech #Phase II trial #Psychedelics #Substance use disorders #Synthetic biology

Phase IIa study will investigate psychedelic for alcohol use disorder

Beckley Psytech has initiated a Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD). BPL-003 is Beckley Psytech’s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Funding #Psychedelics #Start-ups

What will the 2023 drug discovery landscape look like?

Listen to this article on the DDW podcast: DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean. Virtual clinical trials ‘Virtual’ and ‘technology’ are concepts which are readily exchanged in this industry,… Read More

#Exclusive Content #Trends & Analysis

5-Methoxy-N, N-Dimethyltryptamine
#Phase I trial #Psychedelics #Psychiatry #Treatment-resistant depression

Synthetic psychedelic successfully completes Phase I study 

Beckley Psytech has completed its Phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT).  The drug is under development for Treatment Resistant Depression and Alcohol Use Disorder and was assessed in combination with psychological support in 44 psychedelic-naïve participants.  Initial… Read More

#News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

Magic mushrooms
#Depression #Mental health #Psilocybin #Psychedelics #The New England Journal of Medicine #Treatment-resistant depression #Trial data

Study shows ‘magic mushrooms’ could treat depression 

Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind.  The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). Read More

#News #Trending News

Psilocybin
#Biologics / Biotechnology #Drug discovery #Psychedelics

How this biotech is ramping up its psychedelic drug discovery

Psychedelic plants and fungi have been used medicinally by indigenous populations over thousands of years. But while psychedelic drug research has witnessed a relative roller-coaster ride of effort since the mid-20th century, more recent interest in the use of psychedelics for treating mental health and psychiatric disorders has spurred a… Read More

#Exclusive Content

#Antimicrobial resistance (AMR) #Psychedelics #Sickle cell disorder (SCD)

This week in drug discovery (11-15 July)

News round-up by DDW’s Reece Armstrong for 11 – 15 July. Urgency a must for global fight against AMR, report says Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by… Read More

#News

#Business #Investment #Psychedelics

Origin Therapeutics adds Canadian psychedelics company to portfolio  

Origin Therapeutics, an investment company focused on psychedelic therapies, has added Canadian biotech Clairvoyant to its portfolio.  Clairvoyant is developing psychedelic drug therapy focused on addiction and is targeting the clinical validation of psilocybin in the EU, the UK, and Canada. The company is currently proceeding with a Phase II… Read More

#Business & Investment #News

#Biotechnology #Clinical trials #Innovate UK #Psychedelics

Awakn Life Sciences receives UK backing for ketamine therapy  

Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US.   Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The company plans to work with… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Psychedelics

Beckley Psytech partners with Ksana Health to boost clinical trial data  

Clinical stage company Beckley Psytech has partnered with behavioural health company Ksana Health to use the company’s technology to support its future clinical trials.  Beckley Psytech will use Ksana Health’s Effortless Assessment Research System (EARS) to collect passive mobile device meta data from clinical trial participant’s smartphones. Read More

#News

#Drug discovery #Neuroscience #Psychedelics

Experienced neuroscientist joins Beckley Psytech as CMO 

Beckley Psytech, a clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has appointed Frank Wiegand as Chief Medical Officer.  Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where… Read More

#News

#Biotechnology #Clinical trial #Data #Psychedelics

First patient receives low-dose psilocybin for rare headache disorder 

Beckley Psytech has dosed the first patient in a world-first clinical trial exploring the effects of psilocybin for treating Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA).   The outcome of the Phase Ib study, with proof-of-concept efficacy data, is expected to be available in early 2022. The clinical trial is being… Read More

#News